This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.00382-07v1 81/14/7732    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chevaliez, S. Articles by Pawlotsky, J.-M. Search for Related Content PubMed PubMed Citation Articles by Chevaliez, S. Articles by Pawlotsky, J.-M.

 Previous Article  |  Next Article 

Journal of Virology, July 2007, p. 7732-7741, Vol. 81, No. 14
0022-538X/07/$08.00+0     doi:10.1128/JVI.00382-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus Infection

French National Reference Center for Viral Hepatitis B, C and delta, Department of Virology, Hôpital Henri Mondor, Université Paris 12, Créteil, France,¹ INSERM U841, Créteil, France,² Centro de Astrobiología (INTA-CSIC), Torrejón de Ardoz, Madrid, Spain,³ Department of Hepatology and Gastroenterology, Hôpital Henri Mondor, Université Paris 12, Créteil, France⁴

Received 22 February 2007/ Accepted 2 May 2007

The addition of ribavirin to alpha interferon therapy significantly increases response rates for patients with chronic hepatitis C virus (HCV) infection, but ribavirin's antiviral mechanisms are unknown. Ribavirin has been suggested to have mutagenic potential in vitro that would lead to "error catastrophe," i.e., the generation of nonviable viral quasispecies due to the increment in the number of mutant genomes, which prevents the transmission of meaningful genetic information. We used extensive sequence-based analysis of two independent genomic regions in order to test in vivo the hypothesis that ribavirin administration accelerates the accumulation of mutations in the viral genome and that this acceleration occurs only when HCV replication is profoundly inhibited by coadministered alpha interferon. The rate of variation of the consensus sequence, the frequency of mutation, the error generation rate, and the between-sample genetic distance were measured for patients receiving ribavirin monotherapy, a combination of alpha interferon three times per week plus ribavirin, or a combination of alpha interferon daily plus ribavirin. Ribavirin monotherapy did not increase the rate of variation of the consensus sequence, the mutation frequency, the error generation rate, or the between-sample genetic distance. The accumulation of nucleotide substitutions did not accelerate, relative to the pretreatment period, during combination therapy with ribavirin and alpha interferon, even when viral replication was profoundly inhibited by alpha interferon. This study strongly undermines the hypothesis whereby ribavirin acts as an HCV mutagen in vivo.

Published ahead of print on 9 May 2007.

This article has been cited by other articles:

• Heck, J. A., Lam, A. M. I., Narayanan, N., Frick, D. N. (2008). Effects of Mutagenic and Chain-Terminating Nucleotide Analogs on Enzymes Isolated from Hepatitis C Virus Strains of Various Genotypes. Antimicrob. Agents Chemother. 52: 1901-1911 [Abstract] [Full Text]  
• Orihara, Y., Hamamoto, H., Kasuga, H., Shimada, T., Kawaguchi, Y., Sekimizu, K. (2008). A silkworm baculovirus model for assessing the therapeutic effects of antiviral compounds: characterization and application to the isolation of antivirals from traditional medicines. J. Gen. Virol. 89: 188-194 [Abstract] [Full Text]